Hypertension Management

Introduction to Hypertension Management

The European Society of Cardiology recommends a combination of lifestyle modifications and pharmacological therapy for hypertension management, with first-line medications being ACE inhibitors, ARBs, dihydropyridine CCBs, and thiazide/thiazide-like diuretics, targeting a blood pressure of 120-129/70-79 mmHg for most adults if tolerated 1, 2, 3

Diagnosis and Classification

Screen all patients for substances that may increase blood pressure or interfere with blood pressure-lowering medications, as recommended by the American Heart Association 4
Consider seasonal blood pressure variation, with blood pressure typically being lower at higher temperatures and higher at lower temperatures, resulting in an average decline of 5/3 mmHg systolic/diastolic in summer 4

Lifestyle Modifications

Limit sodium intake to less than 100 mEq/24-hour, approximately 2.3g sodium, as recommended by the American Heart Association 4, 5
Engage in at least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity aerobic exercise weekly, complemented with resistance training 2-3 times/week, as recommended by the European Society of Cardiology 3
Aim for a healthy body mass index and waist circumference, as recommended by the European Society of Cardiology 3
Follow a diet rich in whole grains, fruits, vegetables, polyunsaturated fats, and dairy products, similar to the DASH diet, as recommended by the American Heart Association 4
Limit alcohol intake to less than 14 units/week for men and less than 8 units/week for women, preferably avoiding alcohol completely, as recommended by the European Society of Cardiology 1, 3
Stop tobacco use, as it strongly and independently causes cardiovascular disease, as recommended by the European Society of Cardiology 1

Pharmacological Treatment

The European Society of Cardiology recommends the following first-line medications: ACE inhibitors, ARBs, dihydropyridine CCBs, and thiazide/thiazide-like diuretics 1, 3
Initial therapy for most patients with confirmed hypertension should start with combination therapy rather than monotherapy, as recommended by the European Society of Cardiology 1, 3
Preferred combinations include a RAS blocker with either a dihydropyridine CCB or diuretic, as recommended by the European Society of Cardiology 1, 3
Use fixed-dose single-pill combinations when possible to improve adherence, as recommended by the European Society of Cardiology 1, 3
If blood pressure is not controlled with two drugs, use a three-drug combination, typically a RAS blocker plus a dihydropyridine CCB plus a thiazide/thiazide-like diuretic, as recommended by the European Society of Cardiology 1, 3

Special Populations

For black patients, initial treatment should include a diuretic or CCB, either alone or in combination with a RAS blocker, as recommended by the European Society of Cardiology 2
For elderly patients, target systolic blood pressure to 130-139 mmHg, as recommended by the European Society of Cardiology 3
For very elderly patients, consider more lenient targets, less than 140 mmHg, as recommended by the European Society of Cardiology 3
For patients with chronic kidney disease, use RAS blockers as part of the treatment strategy, especially with albuminuria or proteinuria, as recommended by the European Society of Cardiology 2

Blood Pressure Targets

The general target blood pressure is 120-129/70-79 mmHg for most adults if well tolerated, as recommended by the European Society of Cardiology 1, 3
For elderly patients, target systolic blood pressure of 130-139 mmHg, as recommended by the European Society of Cardiology 3

Management of Resistant Hypertension

Resistant hypertension is defined as blood pressure that remains above goal despite adherence to an appropriate three-drug regimen, including a diuretic, as defined by the American Heart Association 5
The approach to managing resistant hypertension includes reinforcing lifestyle measures, adding low-dose spironolactone to existing treatment, and considering other medications, as recommended by the European Society of Cardiology 2, 3, 5

Monitoring and Follow-up

Take medications at the most convenient time of day to establish a habitual pattern and improve adherence, as recommended by the European Society of Cardiology 1
Check blood pressure within 4 weeks of any medication adjustment, as recommended by the European Society of Cardiology 6
Consider using home blood pressure monitoring with a target of less than 135/85 mmHg, as recommended by the European Society of Cardiology 6

Common Pitfalls and Caveats

Nonadherence affects 10-80% of hypertensive patients, simplify regimens when possible, as noted by the American Heart Association 4, 5
Consider adjusting treatment during significant temperature changes due to seasonal variation, as recommended by the American Heart Association 4
Screen for secondary hypertension in young patients and those with resistant hypertension, as recommended by the European Society of Cardiology 2
Avoid monotherapy in high-risk patients, as combination therapy is more effective, as recommended by the European Society of Cardiology 6
Be aware of substances that may interfere with blood pressure control, as recommended by the American Heart Association 4

Management of Resistant Hypertension

Diagnosis and Treatment

The European Society of Cardiology recommends adding low-dose spironolactone to existing treatment as the preferred next step for resistant hypertension, starting with 25 mg daily and monitoring serum potassium and renal function within 1-2 weeks of initiation 7
The patient meets criteria for resistant hypertension, defined as blood pressure that remains above goal despite adherence to an appropriate three-drug regimen that includes a diuretic 8
If spironolactone is not tolerated or contraindicated, consider eplerenone as an alternative mineralocorticoid receptor antagonist, or add a beta-blocker such as bisoprolol, or add an alpha-blocker such as doxazosin 7

Lifestyle Modifications

Dietary sodium restriction to less than 2.3g sodium per day, weight loss if the patient is overweight or obese, regular physical activity, moderation of alcohol intake, and a high-fiber, low-fat diet such as the DASH diet are recommended 8

Monitoring and Referral

Monitor serum potassium and renal function after adding spironolactone, particularly in patients with reduced kidney function 7
If blood pressure remains uncontrolled on ≥3 drugs or if there are multiple drug intolerances, consider referral to a specialist with expertise in hypertension 7

Management of Uncontrolled Hypertension

Medication Optimization

The European Heart Journal recommends optimizing the current medication by replacing atenolol with a more appropriate agent, as beta-blockers are not first-line agents for uncomplicated hypertension in elderly patients unless there are compelling indications, such as coronary artery disease, heart failure, or post-myocardial infarction 9, 10
The European Heart Journal and Hypertension journal suggest that the combination of an angiotensin receptor blocker (ARB) plus thiazide diuretic is a guideline-recommended first-line combination therapy for patients with uncontrolled hypertension 9

Blood Pressure Targets

The Hypertension journal recommends a target blood pressure of <140/90 mmHg minimum for elderly patients 10
The European Society of Cardiology recommends avoiding overly aggressive lowering in elderly patients, particularly diastolic blood pressure below 60 mmHg, as stated in the Circulation journal 11

Lifestyle Modifications

The Hypertension journal suggests that sodium restriction to <2.3g (100 mEq) daily can provide additional blood pressure reduction of 5-10 mmHg 10

Guideline‑Driven Management of Stage 2 Hypertension in Physically Active Adults

First‑Line Therapy Selection

In non‑Black adults with stage 2 hypertension, an ACE inhibitor is considered an appropriate first‑line option and is interchangeable with a thiazide diuretic; the 2017 ACC/AHA hypertension guideline endorses initiating therapy with either class (Class I, Level A)【12】.

Risks of Diuretics in Physically Active Patients

Diuretic therapy is associated with sexual dysfunction, a side‑effect that markedly reduces quality of life and medication adherence【12】.
In individuals who perform vigorous exercise (≈30–60 min daily, six days per week), diuretics may precipitate volume depletion, leading to dehydration, electrolyte imbalance, and impaired athletic performance【13】.

Monitoring and Safety

Baseline and 2–4 week follow‑up measurements of serum potassium and creatinine are recommended after starting an ACE inhibitor to detect hyper‑kalemia or acute kidney injury, which are known class‑related adverse events【12】.
The target blood pressure for most adults is <130/80 mmHg, with a minimum acceptable goal of <140/90 mmHg【12】.
Patients should be advised to temporarily discontinue ACE inhibitors during periods of volume depletion (e.g., illness with vomiting or diarrhea) because this increases the risk of acute kidney injury【13】.
Adequate hydration should be emphasized for physically active patients, as dehydration can compromise blood‑pressure control and heighten the risk of ACE‑inhibitor‑related kidney injury【13】.

Guideline Recommendations on Treatment Approach

For patients who express concerns about sexual side‑effects, clinicians should avoid initiating diuretic therapy because forcing such medication can undermine adherence and the therapeutic relationship【12】.
Even in stage 2 hypertension, it is acceptable to begin with monotherapy and titrate the dose before adding a second agent; combination therapy is not mandatory when patient‑specific factors warrant a stepwise strategy【12】.
If blood pressure remains uncontrolled after optimal ACE‑inhibitor dosing, a calcium‑channel blocker (e.g., amlodipine) should be added before considering a diuretic, preserving the patient’s preference to avoid sexual dysfunction【12】.
When triple therapy becomes necessary, low‑dose thiazide diuretics can be introduced; the risk of sexual dysfunction is lower in this context, and the benefit of achieving blood‑pressure control outweighs the concern【12】.

First‑Line Pharmacologic Management of Isolated Diastolic Hypertension

Guideline‑Recommended First‑Line Agents

The 2017 ACC/AHA guideline identifies five drug classes with proven cardiovascular benefit in high‑quality randomized controlled trials—thiazide diuretics (especially chlorthalidone), ACE inhibitors, ARBs, calcium‑channel blockers, and beta‑blockers. Level A evidence supports their use. 14
Among these, thiazide diuretics and dihydropyridine calcium‑channel blockers are preferred for initial therapy because they provide superior stroke prevention and overall cardiovascular event reduction. Level A evidence. 14

Evidence Gap for Cilnidipine

Cilnidipine has not been evaluated in long‑term cardiovascular outcome trials that demonstrate reductions in mortality or major cardiovascular events. Consequently, it lacks the outcome‑based evidence required for first‑line use. [15][16]
The 1993 British Hypertension Society statement noted that only diuretics and beta‑blockers had been “adequately and extensively tested in long‑term prospective outcome trials”; newer agents such as cilnidipine should be considered only as alternative first‑line agents when standard drugs are contraindicated or cause side effects. Expert consensus. [15][16]
Meta‑analyses show cilnidipine lowers blood pressure to a similar degree as other calcium‑channel blockers, but blood‑pressure reduction alone does not equate to proven cardiovascular mortality or morbidity benefit. Level B evidence (meta‑analysis). 14

Diagnostic Confirmation Before Initiating Therapy

For patients with diastolic BP 90–99 mmHg and no target‑organ damage, repeat measurements over 3–6 months are recommended before starting drug therapy. Expert consensus. 16
Initiate drug therapy immediately when diastolic BP ≥ 100 mmHg or when target‑organ damage is present. Expert consensus. 16

Preferred First‑Line Pharmacologic Options

Thiazide diuretic (chlorthalidone 12.5–25 mg daily or hydrochlorothiazide 25–50 mg daily) is the preferred initial choice because of its proven cardiovascular outcome benefit. Level A evidence. 14
ACE inhibitor (e.g., lisinopril 10–40 mg daily) is an appropriate alternative, especially in younger patients or those with diabetes. Level A evidence. 14
Dihydropyridine calcium‑channel blocker (e.g., amlodipine 5–10 mg daily) is suitable when diuretics or ACE inhibitors are contraindicated. Level A evidence (ACC/AHA) and Level B evidence (European Heart Journal). [14][17]

Blood‑Pressure Targets for Isolated Diastolic Hypertension

Aim for a minimum diastolic BP < 90 mmHg, with an optimal target of < 80 mmHg if tolerated. Expert consensus. 16

Clinical Pitfalls to Avoid

Do not use cilnidipine as first‑line therapy when guideline‑recommended agents with proven cardiovascular outcome data are available and appropriate. Level A evidence (ACC/AHA) and expert consensus (British Hypertension Society). [14][15]
Do not assume that blood‑pressure reduction alone guarantees cardiovascular protection; only agents with demonstrated mortality and morbidity benefits should be first‑line. Level A evidence. 14
Do not employ beta‑blockers as monotherapy for uncomplicated isolated diastolic hypertension, as they are less effective than diuretics and calcium‑channel blockers for stroke prevention. Level A evidence (ACC/AHA) and Level B evidence (European Heart Journal). [14][17]

ESC Guideline Recommendations for Bisoprolol in Isolated Diastolic Hypertension

First‑Line Therapy Recommendations

The 2024 ESC guidelines recommend ACE inhibitors, ARBs, thiazide (or thiazide‑like) diuretics, and dihydropyridine calcium‑channel blockers as the most effective agents for lowering blood pressure and reducing cardiovascular events in patients with isolated diastolic hypertension; bisoprolol is not a first‑line option. 18

Indications When Bisoprolol May Be Appropriate

Bisoprolol should be used only when a patient has a compelling indication such as coronary artery disease, post‑myocardial infarction status, heart failure with reduced ejection fraction, or when heart‑rate control for arrhythmias is required. 18

Use of Bisoprolol as Add‑On Therapy for Resistant Hypertension

In patients whose blood pressure remains uncontrolled despite optimal doses of a renin‑angiotensin system blocker, a dihydropyridine calcium‑channel blocker, and a thiazide diuretic, bisoprolol may be added as a fourth agent. 18

Blood Pressure Targets in Treated Adults

For most adults receiving antihypertensive therapy, the ESC targets are systolic blood pressure 120–129 mmHg and diastolic blood pressure 70–79 mmHg, provided the regimen is well tolerated. 18

Situations to Avoid Bisoprolol Monotherapy

Bisoprolol must not be prescribed as monotherapy for uncomplicated isolated diastolic hypertension when guideline‑endorsed agents with proven mortality and morbidity benefits are available. 18

Confirmation of Absence of Compelling Indications Before Initiation

Clinicians should verify that no compelling indication (e.g., CAD, recent MI, HFrEF, need for heart‑rate control) exists before starting a beta‑blocker for hypertension. 18

Management of Elevated Diastolic Blood Pressure

Blood Pressure Targets

Aim for a diastolic pressure < 80 mmHg in most adults, with a systolic target of 120–129 mmHg when tolerated (European Society of Cardiology) 19.
The minimum acceptable diastolic goal is < 90 mmHg (European Society of Cardiology) 20.
In patients with diabetes, chronic kidney disease, or established cardiovascular disease, the preferred diastolic target is < 80 mmHg (European Society of Cardiology) 21.

Initiation of Pharmacologic Therapy

Start antihypertensive medication immediately when diastolic BP ≥ 90 mmHg, irrespective of cardiovascular risk (European Society of Cardiology) [20][19]22.
For diastolic BP 80–89 mmHg, begin medication after ≥3 months of lifestyle measures if the 10‑year cardiovascular risk is ≥ 10 % or if high‑risk conditions are present (e.g., established CVD, diabetes, CKD, familial hypercholesterolemia, hypertension‑mediated organ damage) (European Society of Cardiology) [22][19]20.

First‑Line Medication Classes

Thiazide or thiazide‑like diuretics (e.g., chlorthalidone 12.5–25 mg daily) are preferred over hydrochlorothiazide because of longer action and superior cardiovascular outcomes (European Society of Cardiology) 19.
ACE inhibitors (e.g., lisinopril 10–40 mg daily) or ARBs (e.g., losartan 50–100 mg daily) are especially beneficial in diabetes, CKD, heart failure, or post‑myocardial infarction (American Diabetes Association; European Society of Cardiology) [20][19].
Dihydropyridine calcium‑channel blockers (e.g., amlodipine 5–10 mg daily) are particularly effective in Black patients and those with isolated diastolic hypertension (European Society of Cardiology) 19.
Beta‑blockers are reserved for compelling indications (angina, post‑MI, HFrEF, atrial fibrillation) and are not first‑line for uncomplicated hypertension (European Society of Cardiology) [19][21].

Combination Therapy

Most patients require ≥2 agents to reach diastolic < 80 mmHg (European Society of Cardiology) [20][19].
Preferred initial combos: an RAS blocker (ACE‑I or ARB) + either a calcium‑channel blocker or a thiazide diuretic (European Society of Cardiology) [19][22].
Fixed‑dose single‑pill combinations should be used when possible to improve adherence (European Society of Cardiology) [19][22].
If BP remains uncontrolled on two drugs, intensify to triple therapy (RAS blocker + calcium‑channel blocker + thiazide diuretic) (European Society of Cardiology) [19][22].

Lifestyle Interventions (Applicable to All Patients)

DASH diet reduces diastolic BP by ≈ 5.5 mmHg; emphasizes fruits, vegetables, whole grains, low‑fat dairy, and minerals while limiting saturated fat and cholesterol (European Society of Cardiology) 19.
Sodium restriction to < 2 g/day (≈ 5 g salt) lowers diastolic BP by 3–5 mmHg and enhances efficacy of diuretics and RAS blockers (European Society of Cardiology) [19][23].
Increased potassium intake via fruits/vegetables or potassium‑enriched salt substitutes (75 % NaCl/25 % KCl) is recommended for patients without CKD or potassium‑sparing drugs (European Society of Cardiology) [19][23]; serum potassium should be monitored when combined with ACE‑I/ARB or spironolactone.
Aerobic exercise ≥ 150 min/week of moderate intensity (or 75 min/week vigorous) reduces diastolic BP by ≈ 3 mmHg (European Society of Cardiology) 19.
Weight loss: a 10 kg reduction yields ≈ 4.6 mmHg diastolic decrease (European Society of Cardiology) 19.
Alcohol limitation to ≤ 1 drink/day (women) or ≤ 2 drinks/day (men) is advised (European Society of Cardiology) 19.
Smoking cessation is essential because tobacco independently drives cardiovascular disease (European Society of Cardiology) 19.

Special Population Considerations

Black patients: calcium‑channel blockers or thiazide diuretics are more effective than ACE‑I/ARBs as monotherapy; combination with an RAS blocker remains appropriate (European Society of Cardiology) 19.
Diabetes with albuminuria: ACE‑I or ARB is strongly recommended as first‑line therapy (American Diabetes Association; European Society of Cardiology) [20][21].
Chronic kidney disease: RAS blockers are preferred, especially with proteinuria (European Society of Cardiology) 21.
Elderly (≥ 65 years): Target systolic < 130 mmHg while avoiding diastolic < 60 mmHg to prevent coronary hypoperfusion (European Society of Cardiology) 19.

Monitoring and Follow‑Up

Re‑measure BP 2–4 weeks after any medication initiation or dose change (European Society of Cardiology) 19.
Aim to achieve target BP within 3 months of starting therapy (European Society of Cardiology) [19][22].
Check serum potassium and creatinine 2–4 weeks after starting an ACE‑I, ARB, or diuretic (European Society of Cardiology) [19][23].
Once BP is controlled, schedule follow‑up every 3–6 months (European Society of Cardiology).

Resistant Hypertension (Diastolic ≥ 90 mmHg on Triple Therapy)

Add spironolactone 25–50 mg daily as the preferred fourth agent, providing an additional 10–12 mmHg diastolic reduction (European Society of Cardiology) 19.
Monitor serum potassium closely when spironolactone is combined with ACE‑I or ARB (European Society of Cardiology) 19.
Screen for secondary causes (primary aldosteronism, renal artery stenosis, obstructive sleep apnea, pheochromocytoma) if BP remains severely elevated (European Society of Cardiology) [19][22].

Common Pitfalls to Avoid

Do not postpone pharmacologic therapy in patients with diastolic ≥ 90 mmHg or with diastolic 80–89 mmHg plus high cardiovascular risk after 3 months of lifestyle measures (European Society of Cardiology) [19][22].
Avoid dual RAS blockade (ACE‑I + ARB) due to increased hyperkalemia and AKI risk without added benefit (European Society of Cardiology) [19][22].
Do not use beta‑blockers as first‑line agents for uncomplicated hypertension; they are less effective for stroke prevention (European Society of Cardiology) [19][21].
Confirm medication adherence before labeling treatment as resistant, as non‑adherence is the most common cause of apparent resistance (European Society of Cardiology) [19][22].
Be aware of BP‑raising substances (NSAIDs, decongestants, oral contraceptives, systemic steroids, certain herbal supplements) and manage accordingly (European Society of Cardiology) 19.
Verify true hypertension with home BP monitoring (≥ 135/85 mmHg) or 24‑hour ambulatory monitoring (≥ 130/80 mmHg) before escalating therapy (European Society of Cardiology) [19][22].